T ubuloglomerular feedback (TGF) is a major component of renal autoregulation, maintaining homeostasis by regulating renal blood flow and glomerular filtration at the single nephron level.
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Methods
Methods are available in the online-only Data Supplement.
Results
We first performed a time control experiment of depolarization-induced TGF. Four consecutive TGF responses were induced by increasing KCl in the MD perfusate from 4 to 50 mmol/L in the presence of the potassium ionophore valinomycin (1 µmol/L), whereas NKCC2 was inhibited with furosemide (100 µmol/L). As shown in Figure 1 , the first TGF response decreased Af-Art diameter by 2.9±0.1 µm (16.8±0.7-13.9±0.8 µm) when the MD perfusate was increased from 4 to 50 mmol/L KCl. Subsequent TGF responses decreased Af-Art diameter by 3.1±0.2, 3.0±0.1, and 3.1±0.2 µm. TGF responses were not significantly different, indicating that depolarizationinduced TGF responses are stable and reproducible over time.
We then determined the effect of CO on TGF elicited by MD depolarization. The first (control) TGF response was 3.6±0.4 µm. Addition of CORM-3, a CO-releasing molecule, to the MD perfusate at a concentration of 50 µmol/L decreased TGF response by 30% to 2.48±0.37 µm, whereas CORM-3 100 µmol/L completely inhibited TGF to 0.1±0.1 µm (n=6; P<0.001; Figure 2A) .
We have previously shown that depolarization of the MD with nystatin causes TGF even when NKCC2 is blocked. 12 Here, we tested whether CO can also inhibit nystatin-induced TGF. We first induced TGF by increasing luminal NaCl concentration in the MD from 10 to 80 mmol/L, causing Af-Art diameter to decrease by 3.0±0.2 µm. We then returned NaCl to 10 mmol/L and added nystatin (100 µmol/L) to the MD lumen in the presence of furosemide, causing Af-Art diameter to decrease by 3.3±0.2 µm. The TGF response induced by nystatin was not significantly different from that induced by high NaCl. When CORM-3 100 µmol/L was added to the MD perfusate, nystatin-induced TGF was completely abolished, 0.4±0.2 µm (n=6; P<0.001 with versus without CORM-3; Figure 2B ). Taken together, these data indicate that CO inhibits TGF acting downstream from depolarization.
To test whether soluble guanylyl cyclase mediates the inhibitory effect of CO on depolarization-induced TGF, the soluble guanylyl cyclase inhibitor LY83583 (1 µmol/L) was added to the MD perfusate. TGF induced by 50 mmol/L KCl and valinomycin was 3.0±0.5 µm. Blockade of cGMP generation with LY83583 did not affect depolarization-induced TGF (2.9±0.4 µm) but completely prevented the inhibitory effect of CORM-3, 50 µmol/L (3.0±0.4 µm). On the contrary, LY83583 only partially prevented the inhibitory effect of CORM-3 100 µmol/L on depolarization-induced TGF because CORM-3 100 µmol/L was still able to reduce TGF to 1.3±0.2 µm (n=9; P<0.02 LY83583 versus LY83583+CORM-3, 100 µmol/L; Figure 3 ). To confirm that cGMP inhibits TGF downstream from MD depolarization, the degradation-resistant cGMP analog db-cGMP (500 µmol/L) was added to the MD perfusate. Addition of db-cGMP attenuated depolarization-induced TGF from 3.9±0.6 µm to 0.6±0.2 µm (n=6; P<0.002 with versus without db-cGMP; Figure 4 ). These data suggest that CO acts via cGMP at low concentrations, but additional mechanisms of action may be involved at higher concentrations. To test whether prostaglandins mediate the cGMP-independent effect of CO on TGF, the cyclooxygenase inhibitor indomethacin (5×10 −5 mol/L) was added to the MD perfusate. TGF induced by 50 mmol/L KCl and valinomycin was 3.0±0.3 µm. Blockade of cGMP generation with LY83583 (10 −5 mol/L, ie, 10-fold higher than in Figure 3 ) did not affect depolarization-induced TGF (3.3±0.5 µm) but partially prevented the inhibitory effect of CORM-3 100 µmol/L on depolarizationinduced TGF because CORM-3 100 µmol/L was still able to reduce TGF to 1.4±0.2 µm (n=6; P<0.01 LY83583 versus LY83583+CORM-3 100 µmol/L). Addition of indomethacin did not block the inhibitory effect of CORM-3 because TGF under these conditions was 0.5±0.5 µm ( Figure 5 ). Furthermore, to test whether any arachidonic acid metabolites from various pathways, such as cytochrome P450, mediated the cGMP-independent effect of CO on TGF, we repeated this experiment using the arachidonic acid analog eicosatetraynoic acid (ETYA; 12.5 µmol/L) instead of indomethacin. Similarly to indomethacin, ETYA did not block the inhibitory effect of CORM-3 because TGF responses under these conditions were 3.7±0.3, 3.8±0.1, 2.0±0.2, and 0.3±0.1 µm, respectively (n=6; Figure S1 in the online-only Data Supplement). These data suggest that the cGMP-independent effect of CO on TGF is not mediated by prostaglandins or other arachidonic acid metabolites.
It has been shown that MD cell membrane depolarization promotes Ca entry 11 and that luminal perfusion with Ca and the Ca ionophore A23187 induced TGF. 13 To determine whether CO inhibits TGF downstream from the increase in intracellular Ca, we tested whether CO inhibits TGF induced by A23187 5 µmol/L added to the MD perfusate. Control TGF was 4.1±0.6 µm. Addition of CORM-3 50 µmol/L decreased the TGF response to 1.9±0.6 µm, whereas CORM-3 100 µmol/L completely inhibited TGF, 0.2±0.5 µm (n=6; P<0.001; Figure 6A ). To ensure that the observed attenuation of TGF was attributable to the addition of CORM-3 rather than a time effect causing waning of A23187-induced TGF, we performed a time control experiment. Ca ionophore-induced TGF remained stable during the experimental period (n=6; Figure 6B ). These data suggest that CO inhibits TGF downstream from intracellular Ca increase.
Discussion
We have previously reported that CO, either endogenous or exogenous, inhibits TGF, and that the mechanism for this effect is at least in part via the cGMP/protein kinase G/cAMP pathway. 19 In the present study, we found that depolarization of MD by either high KCl with valinomycin or nystatin initiates TGF; CO blunts depolarization-induced TGF at a low concentration and abolishes it at a higher concentration; blockade of cGMP generation with the guanylyl cyclase inhibitor LY83583 completely prevents the inhibitory effect of low doses of CO on depolarization-induced TGF; blockade of cGMP generation can only partially prevent the inhibitory effect of higher doses of CO; addition of the cell-permeant, phosphodiesterase-resistant cGMP analog db-cGMP to the MD perfusate blunts depolarization-induced TGF; neither indomethacin nor ETYA blocked the cGMP-independent effect of CO on TGF; and CO blunts Ca ionophore-induced TGF. We believe that our data are the first to show that CO inhibits TGF acting downstream from depolarization.
We have previously reported that the HO system inhibits TGF because inhibiting tubular HOs with stannous mesoporphyrin potentiated TGF, whereas adding exogenous CO to the MD inhibited TGF. CO has profound effects on the intracellular signaling processes in many tissues. One of CO's main mechanisms of action is by binding to the heme moiety of soluble guanylyl cyclase, thus leading to the stimulation of soluble guanylyl cyclase and subsequent elevation of cGMP. 20 In previous studies, we have shown that CO can attenuate TGF that was induced by increasing luminal NaCl in the MD. 19 Under those conditions, TGF depends on NKCC2 activity, and presumably, CO acts similarly to NO, inhibiting NKCC2 via the soluble guanylyl cyclase/cGMP system (ie, CO would act before depolarization). To identify whether CO also acts after depolarization, TGF responses were induced by high KCl and valinomycin, which cause MD membrane depolarization. We have evidence that during inhibition of NKCC2 with furosemide, depolarization of the MD elicits TGF. 12 In this study, we demonstrated that CO inhibits TGF induced by depolarization. To exclude possible spurious effects, such as CO, causing some interference with the ionophore valinomycin, we repeated our studies but with the cation ionophore nystatin, which causes sodium entry and membrane depolarization. Results resembled those of KCl/valinomycin-induced cell depolarization.
Interestingly, we found that inhibition of soluble guanylyl cyclase completely prevents the inhibitory effect of lower concentrations of CO on depolarization-induced TGF, but higher concentrations of CO recruit an additional, cGMPindependent mechanism that inhibits TGF. On the basis of our previous publications, we can exclude a toxic effect of CO on the MD because the effect of CORM-3 100 µmol/L was completely reversible. 21 We considered the possibility that high concentrations of CO could in fact still be acting through cGMP by outcompeting the soluble guanylyl cyclase inhibitor LY83583 for the binding to guanylyl cyclase. However, this is unlikely to be the case because increasing the concentration of the inhibitor 10-fold did not abolish the remaining effect of CORM-3, thus confirming that CO has cGMP-independent effects on the MD.
The exact nature of the cGMP-independent effect of CORM-3 remains elusive. Most actions of CO derive from its very high affinity to bind heme. Heme functions as the prosthetic group in hemeproteins, many of which are enzymes, such as guanylyl cyclase, and the binding of CO can affect their enzymatic activity. 22, 23 At least 2 hemeproteins with enzymatic activity, cyclooxygenase (COX) 24 and NADPH oxidase (NOX), 25 are present in the MD and are known to modulate TGF, thus constituting potential targets for the cGMP-independent effect of CO on TGF. Two isoforms of COX (COX-1 and COX-2) are expressed in the MD, and there is evidence that COX-2-derived prostaglandins may attenuate TGF. 26, 27 In addition, there is some evidence that CO may increase the formation of prostaglandins by activating COX at least in the brain. 28, 29 We tested the possibility that part of the effect of CO was attributable to the release of arachidonic acid metabolites from the MD, either prostanoids (from COX) or CYP450 metabolites (because CYP450 is itself a hemeprotein). However, we found that blockade of COX did not prevent the effect of CO. To further test the participation of other arachidonic acid metabolites, we studied whether the arachidonic acid analog ETYA could prevent the effect of CO, but again the effect of CO was not prevented. These data suggest that an alternative target of CO may exist in the MD, but unlikely to be related to arachidonic acid metabolites.
Interestingly, both ETYA and indomethacin had the opposite effect from our hypothesis (ie, not only did they fail to prevent the inhibitory effect of CO but also they themselves had an inhibitory effect on TGF induced by depolarization). Although not part of our hypothesis, these results also shed light on the role of arachidonic acid metabolites on TGF, that is in agreement with previous literature suggesting that arachidonic acid metabolites, including 20-hydroxyeicosatetraenoic acid 30 and thromboxane A 2 , 31 mediate the constrictor effect of TGF. Although at the present time, we do not have an explanation for the cGMP-independent effect of CO, one alternative is that CO may inhibit O 2 − production, which would attenuate TGF. NOX are hemeproteins 25 that produce superoxide (O 2 − ). Two NOX isoforms are present in the MD, NOX2 and NOX4, with NOX2 being the main isoform responsible for O 2 − production. 32 We have previously reported that O 2 − in the MD potentiates TGF. 33 CO can bind the heme moiety in NOX, but unlike its effect on guanylyl cyclase and COX, binding of CO to NOX results in its inhibition. 34 Furthermore, it has been shown that CO can inhibit NOX in thick ascending limb cells, in a cGMP-independent manner. 35 Therefore, NOX represents a potential target for the effect of CO on TGF, in addition to soluble guanylyl cyclase.
When we added the soluble guanylyl cyclase inhibitor LY83583 to our preparation and induced MD cell depolarization, we found that LY83583 did not affect TGF compared with control (vehicle) TGF (Figure 4 ). This was different from what we have previously found on NaClinduced TGF. 14, 18, 19 One likely explanation is that both luminal NaCl and cell depolarization with KCl/valinomycin induce TGF, but only luminal NaCl induces the concomitant production of NO, which partially attenuates TGF. This assertion is based on our previous observations that luminal NaCl in the MD induces NO production 14 in a manner that is independent of cell depolarization. Rather, luminal NaCl induces NO production via the Na/H exchanger, leading to an increase in intracellular pH, and increases in intracellular pH in turn lead to increased NO production by NO synthase 1, a pH-sensitive enzyme. 36 In addition, we have previously shown that MD depolarization induces the production of O 2 − via NOX, 37 which would further reduce the bioavailability of NO. Thus, when TGF is induced by MD depolarization without simultaneously stimulating the production of NO/cGMP, it is not unexpected that the soluble guanylyl cyclase inhibitor is devoid of effect on basal TGF.
How depolarization induces TGF is not known, however, Ca seems to be involved. Peti-Peterdi and Bell 11 showed that increasing lumen NaCl elevated cytosolic Ca concentration through a signaling pathway that includes NKCC2, basolateral membrane depolarization via Cl channels, and Ca entry through voltage-gated Ca channels. It was therefore reasoned that this large depolarization of membrane voltages, in the presence of high NaCl at the MD, could promote Ca entry across the basolateral membrane. We have shown that increasing Ca entry via the Na/Ca exchanger in the MD is necessary for the induction of TGF. 13 Furthermore, induction of Ca entry by use of a Ca ionophore causes TGF, suggesting that the increase in intracellular Ca concentration is sufficient to stimulate the TGF. 13, 38 Ca plays an important role in intracellular signal transduction by activating transport processes or stimulating the release of a chemical mediator. Previous micropuncture studies showed that a cytosolic Ca system is involved in MD cell signaling. 39 To determine whether CO inhibits TGF downstream from the increase in intracellular Ca, we perfused the lumen of the MD with the Ca ionophore A23187 and measured Af-Art diameter, while adding CORM-3 to the MD perfusate. We found that CO inhibits TGF induced by the Ca ionophore in dose-dependent manner.
Perspectives
Our present studies shed light on both the physiological cascade of events that occur in the MD and result in TGF, and the regulation of such cascade by CO. We have shown for the first time that TGF is subject to regulation downstream from MD cell depolarization by CO and cGMP. We have also expanded our knowledge of the actions of CO on TGF, which are complex, possibly involving effects of both upstream and downstream from cell depolarization, both cGMP-dependent and cGMP-independent. By inhibiting TGF, CO will favor Af-Art dilation and increased renal blood flow, and these effects may help explain the antihypertensive and natriuretic actions of CO. These actions may be particularly relevant in conditions that increase oxidative stress and angiotensin II because such conditions are known inducers of HO-1 40 but decrease NO in the MD. 33, 41 Furthermore, our findings may help explain how TGF is attenuated in diabetes mellitus, a condition with high O 2 − (and presumably low MD NO bioavailability) 42 but with increased HO-1 activity.
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What Is New?
• We studied mechanisms by which CO affects tubuloglomerular feedback (TGF).
• Our data are the first to show that CO inhibits TGF acting downstream from depolarization.
What Is Relevant?
• The kidney plays a key role in high blood pressure. Kidney diseases cause hypertension, and hypertension can in turn damage the kidney.
• By inhibiting TGF, CO will favor afferent arteriole dilation and increase renal blood flow. These effects may help explain the antihypertensive and natriuretic actions of CO.
• Our studies will help to better understand the control of the renal microcirculation.
Summary
To summarize, we found that depolarization of macula densa by high KCl with valinomycin, nystatin, and Ca ionophore initiates TGF; CO blunts depolarization-induced TGF at a low concentration and abolishes it at a higher concentration; blockade of cGMP generation completely prevents the inhibitory effect of low doses of CO, but only partially prevents the inhibitory effect of higher doses of CO; addition of dibutyryl-cGMP to the macula densa blunts depolarizationinduced TGF; and neither indomethacin nor eicosatetraynoic acid blocked the cGMP-independent effect of CO on TGF. We conclude that CO inhibits TGF acting downstream from depolarization and calcium entry, acting via cGMP at low concentrations, but additional mechanisms of action may be involved at higher concentrations.
